Eric G. Campbell, a University of Colorado health-policy expert who has done extensive research on the impact of financial conflicts of interest in medicine, said Califf’s past ties with industry should not disqualify him. “To my knowledge those relationships have been fully discussed and widely debated in the academic and political arena,” Campbell said, adding that many academic trials are underwritten by drug companies.